Versican Plus BbPi IN
Active substance
ATC code
Species
Dogs
Indications
Active immunisation of dogs from 3 weeks of age:
- to reduce clinical signs and bacterial excretion after infection with Bordetella bronchiseptica and
- to reduce clinical signs and viral excretion after infection with canine parainfluenza virus.
Onset of immunity: | 3 days after primary vaccination for Bordetella bronchiseptica. |
7 days after primary vaccination for canine parainfluenza virus. |
Duration of immunity: 1 year.
Dose to be administered and administration route
Nasal use.
Dosage and route of administration:
Aseptically reconstitute the lyophilisate with the solvent. Shake well after reconstitution. Withdraw the liquid with the syringe, remove the needle and administer directly from the tip of the syringe into one nostril. Alternatively, an intranasal applicator (available separately) can be attached to the syringe and the dose then administered into one nostril. The vaccine should then be used immediately.
The head of the dog should be held with the nose pointing upwards. Administer one dose (0.5 ml) of the reconstituted vaccine into one nostril.
Reconstituted vaccine: Whitish to yellowish colour with a slight opalescence.
Primary vaccination scheme:
A single dose from 3 weeks of age.
Re-vaccination scheme:
A single dose to be given annually.
Adverse reactions
Transient mild nasal discharge is very commonly, mild ocular discharge and mild depression are commonly and mild sneezing is uncommonly observed in animals after vaccination. These signs generally subside without treatment within one to three days. Mild to moderate coughing was commonly observed in vaccinated kenneled dogs from nine days after vaccination when housed together with non-vaccinated dogs.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).